/ENGN
ENGN Stock - enGene Holdings Inc.
Healthcare|BiotechnologyNASDAQ
$8.69+6.36%
+$0.52 (+6.36%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+160.9%upside
Target: $22.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ENGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.60 – $8.78
TARGET (TP)$22.67
STOP LOSS$7.99
RISK/REWARD1:20.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.27
52W High$11.14
52W Low$2.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-323,000 | $-175,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $62.30M | $-26,060,000 | $-1,831,421 | $-15,870,000 | $-13,853,000 |
| Net Income | $-55,142,000 | $-99,917,000 | $30,726 | $-23,441,000 | $-15,068,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.46 | $-4.24 | $0.00 | $-0.01 | $-0.95 |
Company Overview
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Visit WebsiteRating Distribution
Strong Buy
1
11%
Buy / Outperform
7
78%
Hold / Neutral
1
11%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish1 Neutral/Bearish
Price Targets
$27
Average Target
↑ 214.5% Upside
Now
$7
Low
$27
Average
$40
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 11th 2025 | Raymond James | Upgrade | Strong Buy | $27 |
| February 18th 2025 | Piper Sandler | Initiation | Overweight | $26 |
| February 14th 2025 | UBS | Downgrade | Neutral | $7← $34 |
| December 23rd 2024 | H.C. Wainwright | Initiation | Buy | $25 |
| November 27th 2024 | Raymond James | Initiation | Outperform | $23 |
| November 18th 2024 | JMP Securities | Initiation | Mkt Outperform | $18 |
| August 28th 2024 | Oppenheimer | Initiation | Outperform | $30 |
| April 22nd 2024 | Wells Fargo | Initiation | Overweight | $30 |
| April 15th 2024 | Guggenheim | Initiation | Buy | $34 |
| March 28th 2024 | UBS | Initiation | Buy | $37 |
| March 8th 2024 | Morgan Stanley | Initiation | Overweight | $40 |
| February 20th 2024 | Leerink Partners | Initiation | Outperform | $31 |
Earnings History & Surprises
ENGNBeat Rate
43%
Last 7 quarters
Avg Surprise
-6.5%
EPS vs Estimate
Beats / Misses
3/4
Last 12 quarters
Latest EPS
$-0.57
Q3 2025
EPS Surprise History
Q4 23
No data
Q1 24
-11.3%
$-0.46vs$-0.41
Q2 24
-46.2%
$-0.38vs$-0.26
Q3 24
+13.5%
$-0.32vs$-0.37
Q4 24
+28.7%
$-0.34vs$-0.48
Q1 25
-29.7%
$-0.48vs$-0.37
Q2 25
-2.0%
$-0.51vs$-0.50
Q3 25
+1.4%
$-0.57vs$-0.58
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Dec 18, 2025 | $-0.55 | — | — | — |
Q3 2025 | Sep 11, 2025 | $-0.58 | $-0.57 | +1.4% | ✓ BEAT |
Q2 2025 | Jun 12, 2025 | $-0.50 | $-0.51 | -2.0% | ✗ MISS |
Q1 2025 | Mar 10, 2025 | $-0.37 | $-0.48 | -29.7% | ✗ MISS |
Q4 2024 | Dec 20, 2024 | $-0.48 | $-0.34 | +28.7% | ✓ BEAT |
Q3 2024 | Sep 10, 2024 | $-0.37 | $-0.32 | +13.5% | ✓ BEAT |
Q2 2024 | Jun 14, 2024 | $-0.26 | $-0.38 | -46.2% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.41 | $-0.46 | -11.3% | ✗ MISS |
Q4 2023 | Oct 31, 2023 | — | $-2.64 | — | — |
Q3 2023 | Jul 31, 2023 | — | $-0.30 | — | — |
Q2 2023 | Apr 30, 2023 | — | $-0.33 | — | — |
Q1 2023 | Jan 31, 2023 | — | $-0.47 | — | — |
Q4 2022 | Oct 31, 2022 | — | $-0.53 | — | — |
Q3 2022 | Jul 31, 2022 | — | $-0.43 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-0.34 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.01 | — | — |
Latest News
enGene Holdings Says FDA Selects Detalimogene Voraplasmid To Participate In Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program
📈 PositiveBenzinga•Dec 2, 2025, 12:37 PM
ENGN stock has given up its prior gain. enGene Holdings shares were trading higher.
➖ NeutralBenzinga•Nov 13, 2025, 03:44 PM
enGene Holdings shares are trading higher. The company announced a $130 million public offering.
📈 PositiveBenzinga•Nov 13, 2025, 01:59 PM
enGene Prices $130M Public Offering Of 12,558,823 Common Shares At $8.50 And 2,735,295 Pre Funded Warrants At $8.4999
➖ NeutralBenzinga•Nov 13, 2025, 06:23 AM
enGene Announces Proposed Public Offering Of Common Shares, Size Not Disclosed
➖ NeutralBenzinga•Nov 12, 2025, 09:14 PM
Morgan Stanley Maintains Overweight on enGene Holdings, Raises Price Target to $19
📈 PositiveBenzinga•Nov 12, 2025, 05:16 PM
Oppenheimer Reiterates Outperform on enGene Holdings, Raises Price Target to $33
📈 PositiveBenzinga•Nov 12, 2025, 04:41 PM
UBS Maintains Neutral on enGene Holdings, Raises Price Target to $10
➖ NeutralBenzinga•Nov 12, 2025, 02:27 PM•Also:
Citizens Maintains Market Outperform on enGene Holdings, Raises Price Target to $21
📈 PositiveBenzinga•Nov 12, 2025, 02:16 PM
enGene Holdings Shares Resume Trade
➖ NeutralBenzinga•Nov 11, 2025, 03:15 PM
EnGene shares are trading higher after the company reported additional Phase 2 LEGEND study data showing a 63% complete response rate and favorable safety profile for Detalimogene Voraplasmid.
📈 PositiveBenzinga•Nov 11, 2025, 01:08 PM
EnGene's Additional Data From Phase 2 LEGEND Study Of Detalimogene Voraplasmid Demonstrates Enhanced Complete Response Rate Of 63% In 62 Participants; Overall Safety Of Detalimogene Favorable
📈 PositiveBenzinga•Nov 11, 2025, 12:36 PM
Morgan Stanley Maintains Overweight on enGene Holdings, Lowers Price Target to $18
➖ NeutralBenzinga•Sep 12, 2025, 03:52 PM
HC Wainwright & Co. Reiterates Buy on enGene Holdings, Maintains $25 Price Target
📈 PositiveBenzinga•Sep 12, 2025, 10:27 AM
enGene Posts 78% Expense Jump in Q3
📉 NegativeThe Motley Fool•Sep 11, 2025, 08:38 PM
enGene Holdings Q3 EPS $(0.57) Misses $(0.51) Estimate
📉 NegativeBenzinga•Sep 11, 2025, 08:04 PM
HC Wainwright & Co. Reiterates Buy on enGene Holdings, Maintains $25 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 11:42 AM
enGene Holdings Reaches Target Enrollment Of 100 Patients For Pivotal Cohort Of Its Ongoing, Open-Label, Multi-Cohort Phase 2 LEGEND Trial Of Detalimogene Voraplasmid In Patients With High-Risk, NMIBC
📈 PositiveBenzinga•Sep 3, 2025, 11:35 AM
Frequently Asked Questions about ENGN
What is ENGN's current stock price?
enGene Holdings Inc. (ENGN) is currently trading at $8.69 per share. The stock has moved +6.36% today.
What is the analyst price target for ENGN?
The average analyst price target for ENGN is $22.67, based on 1 analyst.
What sector is enGene Holdings Inc. in?
enGene Holdings Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ENGN's market cap?
enGene Holdings Inc. has a market capitalization of $0.44 billion, making it a small-cap company.
Does ENGN pay dividends?
No, enGene Holdings Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
ANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to ENGN for comparison